Pangaea Oncology, S.A. (BME:PANG)

Spain · Delayed Price · Currency is EUR

1.470

0.00 (0.00%)

Oct 26, 2026, 4:00 PM CET

Market Cap	52.79M -9.6%
Revenue (ttm)	14.52M +1.8%
Net Income	-3.60M
EPS	-0.10
Shares Out	35.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,600
Open	1.470
Previous Close	1.470
Day's Range	1.470 - 1.470
52-Week Range	1.430 - 1.750
Beta	0.03
Analysts	n/a
Price Target	n/a
Earnings Date	May 12, 2026

About Pangaea Oncology

Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling and transcriptomic signatures; and tumor mutational burden (TMB) and microsatellite instability and (MSI) assessment services. It also provides diagnost... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 2006

Employees 165

Stock Exchange Madrid Stock Exchange

Ticker Symbol PANG

Full Company Profile

Financial Performance

In 2025, Pangaea Oncology's revenue was 14.52 million, an increase of 1.78% compared to the previous year's 14.27 million. Losses were -3.60 million, 208.3% more than in 2024.

Financial Statements